Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I

Sung Hyeok Hong, Joseph Briggs, Rachel Newman, Karen Hoffman, Arnulfo Mendoza, Derek LeRoith, Lee Helman, Shoshana Yakar, Chand Khanna

Research output: Contribution to journalArticle

Abstract

The insulin-like growth factor I (IGF-I) signaling pathway has been shown to play an important role in several aspects of cancer biology, including metastasis. The aim of this study was to define the contribution of serum (endocrine) and local (tumour microenvironment) IGF-I on osteosarcoma tumour growth and metastasis, a cancer that is known to be dependent on the IGF-I axis. To test this hypothesis, we evaluated the primary tumour growth and metastatic progression of K7M2 murine osteosarcoma cells injected to a genetically engineered mouse [liver-specific IGF-I de-ficient (LID)] in which serum IGF-I levels are reduced by 75%, while maintaining expression of IGF-I in normal tissues. We first demonstrated that IGF-I in the tumour and the tumour-microenvironment were maintained in the LID mice. Within this designed model, there was no difference in primary tumour growth or in pulmonary metastasis in LID mice compared to control mice. Furthermore, there was no difference in the number or localization of single metastatic cells immediately after their arrival in the lungs of LID mice and control mice, as analysed by single cell video microscopy. Collectively, these data suggest that marked reduction in serum IGF-I is not sufficient to slow the progression of either primary or metastatic models of osteosarcoma.

Original languageEnglish (US)
Pages (from-to)2042-2049
Number of pages8
JournalInternational Journal of Cancer
Volume124
Issue number9
DOIs
StatePublished - May 1 2009

Fingerprint

Osteosarcoma
Insulin-Like Growth Factor I
Growth
Serum
Tumor Microenvironment
Liver
Neoplasms
Neoplasm Metastasis
Video Microscopy
Lung

Keywords

  • Insulin-like growth factor I
  • Murine
  • Osteosarcoma
  • Pulmonary metastasis
  • Tumour microenvironment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. / Hong, Sung Hyeok; Briggs, Joseph; Newman, Rachel; Hoffman, Karen; Mendoza, Arnulfo; LeRoith, Derek; Helman, Lee; Yakar, Shoshana; Khanna, Chand.

In: International Journal of Cancer, Vol. 124, No. 9, 01.05.2009, p. 2042-2049.

Research output: Contribution to journalArticle

Hong, Sung Hyeok ; Briggs, Joseph ; Newman, Rachel ; Hoffman, Karen ; Mendoza, Arnulfo ; LeRoith, Derek ; Helman, Lee ; Yakar, Shoshana ; Khanna, Chand. / Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. In: International Journal of Cancer. 2009 ; Vol. 124, No. 9. pp. 2042-2049.
@article{83400b9bc41a477c883950a2a5f1cff8,
title = "Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I",
abstract = "The insulin-like growth factor I (IGF-I) signaling pathway has been shown to play an important role in several aspects of cancer biology, including metastasis. The aim of this study was to define the contribution of serum (endocrine) and local (tumour microenvironment) IGF-I on osteosarcoma tumour growth and metastasis, a cancer that is known to be dependent on the IGF-I axis. To test this hypothesis, we evaluated the primary tumour growth and metastatic progression of K7M2 murine osteosarcoma cells injected to a genetically engineered mouse [liver-specific IGF-I de-ficient (LID)] in which serum IGF-I levels are reduced by 75{\%}, while maintaining expression of IGF-I in normal tissues. We first demonstrated that IGF-I in the tumour and the tumour-microenvironment were maintained in the LID mice. Within this designed model, there was no difference in primary tumour growth or in pulmonary metastasis in LID mice compared to control mice. Furthermore, there was no difference in the number or localization of single metastatic cells immediately after their arrival in the lungs of LID mice and control mice, as analysed by single cell video microscopy. Collectively, these data suggest that marked reduction in serum IGF-I is not sufficient to slow the progression of either primary or metastatic models of osteosarcoma.",
keywords = "Insulin-like growth factor I, Murine, Osteosarcoma, Pulmonary metastasis, Tumour microenvironment",
author = "Hong, {Sung Hyeok} and Joseph Briggs and Rachel Newman and Karen Hoffman and Arnulfo Mendoza and Derek LeRoith and Lee Helman and Shoshana Yakar and Chand Khanna",
year = "2009",
month = "5",
day = "1",
doi = "10.1002/ijc.24169",
language = "English (US)",
volume = "124",
pages = "2042--2049",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I

AU - Hong, Sung Hyeok

AU - Briggs, Joseph

AU - Newman, Rachel

AU - Hoffman, Karen

AU - Mendoza, Arnulfo

AU - LeRoith, Derek

AU - Helman, Lee

AU - Yakar, Shoshana

AU - Khanna, Chand

PY - 2009/5/1

Y1 - 2009/5/1

N2 - The insulin-like growth factor I (IGF-I) signaling pathway has been shown to play an important role in several aspects of cancer biology, including metastasis. The aim of this study was to define the contribution of serum (endocrine) and local (tumour microenvironment) IGF-I on osteosarcoma tumour growth and metastasis, a cancer that is known to be dependent on the IGF-I axis. To test this hypothesis, we evaluated the primary tumour growth and metastatic progression of K7M2 murine osteosarcoma cells injected to a genetically engineered mouse [liver-specific IGF-I de-ficient (LID)] in which serum IGF-I levels are reduced by 75%, while maintaining expression of IGF-I in normal tissues. We first demonstrated that IGF-I in the tumour and the tumour-microenvironment were maintained in the LID mice. Within this designed model, there was no difference in primary tumour growth or in pulmonary metastasis in LID mice compared to control mice. Furthermore, there was no difference in the number or localization of single metastatic cells immediately after their arrival in the lungs of LID mice and control mice, as analysed by single cell video microscopy. Collectively, these data suggest that marked reduction in serum IGF-I is not sufficient to slow the progression of either primary or metastatic models of osteosarcoma.

AB - The insulin-like growth factor I (IGF-I) signaling pathway has been shown to play an important role in several aspects of cancer biology, including metastasis. The aim of this study was to define the contribution of serum (endocrine) and local (tumour microenvironment) IGF-I on osteosarcoma tumour growth and metastasis, a cancer that is known to be dependent on the IGF-I axis. To test this hypothesis, we evaluated the primary tumour growth and metastatic progression of K7M2 murine osteosarcoma cells injected to a genetically engineered mouse [liver-specific IGF-I de-ficient (LID)] in which serum IGF-I levels are reduced by 75%, while maintaining expression of IGF-I in normal tissues. We first demonstrated that IGF-I in the tumour and the tumour-microenvironment were maintained in the LID mice. Within this designed model, there was no difference in primary tumour growth or in pulmonary metastasis in LID mice compared to control mice. Furthermore, there was no difference in the number or localization of single metastatic cells immediately after their arrival in the lungs of LID mice and control mice, as analysed by single cell video microscopy. Collectively, these data suggest that marked reduction in serum IGF-I is not sufficient to slow the progression of either primary or metastatic models of osteosarcoma.

KW - Insulin-like growth factor I

KW - Murine

KW - Osteosarcoma

KW - Pulmonary metastasis

KW - Tumour microenvironment

UR - http://www.scopus.com/inward/record.url?scp=63449132960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449132960&partnerID=8YFLogxK

U2 - 10.1002/ijc.24169

DO - 10.1002/ijc.24169

M3 - Article

C2 - 19132750

AN - SCOPUS:63449132960

VL - 124

SP - 2042

EP - 2049

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -